Astra, Lilly stick with Alzheimer's approach despite setback

FRANKFURT (Reuters) - AstraZeneca will expand its collaboration with Eli Lilly to develop an experimental Alzheimer's drug, sticking with an approach that has been a mainstay of research despite recent setbacks.